NIH Highlighted Topic: BRAIN Initiative: Advancing Human Neuroscience and Precision Molecular Therapies for Transformative Treatments
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is encouraging innovative research proposals focused on advancing human neuroscience and precision molecular therapies through the NIH BRAIN Initiative. This highlighted topic supports multidisciplinary efforts to better understand human neural circuits, develop transformative neurotechnologies, and accelerate the translation of neuroscience discoveries into targeted clinical therapies and next-generation brain-interfacing technologies.
NIH is particularly interested in projects that generate new insights into human brain function, develop technologies for monitoring and modulating neural circuits, and create precision molecular therapies capable of correcting dysfunctional brain activity in neurological and neuropsychiatric disorders. Companies developing neurotechnology devices, brain-computer interfaces (BCIs), neural monitoring systems, optogenetic or chemogenetic therapies, precision neuromodulation platforms, AI-enabled neuroscience technologies, or molecular delivery systems may be strong candidates for funding.
Areas of interest include advanced neural effector technologies, genetic delivery systems, neural circuit mapping, precision neuromodulation, engineered control of neural activity, clinical neurotechnology platforms, early-stage human neuroscience studies, data integration systems, and personalized molecular therapies. NIH is also encouraging projects focused on interoperability, standardization, technology dissemination, and sex-specific neuroscience research to improve translation and adoption of novel therapies.
Funding is available through the NIH SBIR/STTR Program, which currently provides up to approximately $323,090 for Phase I projects and up to $2,153,927 for Phase II projects, with opportunities for follow-on funding and commercialization support depending on project scope and translational impact.
This highlighted topic is supported by multiple NIH Institutes and Centers participating in the BRAIN Initiative, including NINDS, NIMH, NIBIB, NIA, NIDA, NIDCD, NEI, NCCIH, OBSSR, and ORWH, all of which are seeking transformative innovations that advance precision neuroscience, neural circuit therapeutics, and next-generation neurotechnology development.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of neurotechnology platforms, neural therapeutics, precision molecular therapies, brain-computer interfaces, and neuroscience data systems.
Eligible activities may include:
Brain-computer interface (BCI) and neural interface technologies
Neural monitoring and neuromodulation systems
Optogenetic and chemogenetic therapeutic platforms
Precision molecular circuit therapy development
Genetic delivery systems for neurological treatments
AI and machine learning platforms for neuroscience and neural analytics
Neurotechnology devices for monitoring and modulating brain activity
Advanced neural effector and stimulation technologies
Personalized and sex-specific neurological therapeutic platforms
Computational neuroscience and neural circuit modeling systems
Human neuroscience research platforms and translational studies
Neural data integration, interoperability, and standardization systems
Wearable and implantable neurotechnology devices
Clinical neurotechnology testing and validation platforms
Neuropsychiatric and neurological disorder treatment technologies
Early-stage human neuroscience and translational research systems
Prototype development, preclinical validation, and pilot human studies
Commercialization planning, regulatory preparation, and manufacturing scale-up activities
Funding may also support personnel, laboratory testing, software engineering, cloud computing infrastructure, AI model development, neural device prototyping, clinical validation studies, genetic engineering research, bioinformatics analysis, intellectual property protection, regulatory strategy, and commercialization activities necessary to advance a scalable and commercially viable neuroscience or neurotechnology solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
